Verrica Pharmaceuticals Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Verrica Pharmaceuticals Inc. (VRCA) is a dermatology therapeutics company that develops and commercializes medications for skin diseases requiring medical intervention; its commercial portfolio centers on YCANTH (VP-102), a proprietary drug-device combination product featuring a GMP-controlled topical formulation of cantharidin delivered via a single-use precision applicator, approved by the U.S. FDA in 2023 as the first therapy for molluscum contagiosum in adult and pediatric patients aged two years and older; the company advances YCANTH (VP-102) in a Phase 3 program for common warts, with targeted first patient enrollment in the U.S. before year-end 2025 and a co-sponsored global trial with partner Torii Pharmaceutical funded initially by Torii; its pipeline also includes VP-315 (formerly LTX-315), an oncolytic peptide-based injectable therapy licensed worldwide from Lytix Biopharma for non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, following positive top-line Phase 2 results in basal cell carcinoma. Founded in 2013 and headquartered at 44 West Gay Street, Suite 400, in West Chester, Pennsylvania, Verrica operates primarily in the U.S. market while pursuing global partnerships outside Japan; it targets dermatologists, pediatricians, and primary care providers serving patients with viral and oncologic skin conditions affecting millions annually. Recent developments encompass a $50 million private placement financing in November 2025, led by existing and new investors with TD Cowen as sole placement agent, to fully retire $35 million in debt under its OrbiMed credit agreement, extend cash runway into mid-2027, and support pipeline advancement; Torii Pharmaceutical's regulatory approval of YCANTH in Japan in September 2025, triggering a $10 million milestone payment to Verrica while it retains global rights outside Japan; and an amended collaboration with Torii securing $8 million upon Phase 3 common warts trial initiation as early as mid-2025.
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Verrica Pharmaceuticals Q1 Earnings Call Highlights
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
Critical Survey: Verrica Pharmaceuticals (NASDAQ:VRCA) vs. Vivani Medical (NASDAQ:VANI)
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA
Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026